Plus Therapeutics, Inc.
PSTV
$5.50
-$0.03-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.46% | -10.49% | -8.16% | -3.49% | -14.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.46% | -10.49% | -8.16% | -3.49% | -14.43% |
| Cost of Revenue | -0.89% | -20.80% | -31.86% | -25.66% | 1.09% |
| Gross Profit | 1.40% | 33.43% | 56.69% | 48.65% | -28.97% |
| SG&A Expenses | 37.96% | 22.06% | 20.67% | 14.25% | 24.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.49% | -0.04% | -8.17% | -7.77% | 11.99% |
| Operating Income | -26.45% | -4.10% | 8.17% | 9.44% | -25.50% |
| Income Before Tax | 56.00% | -72.49% | -59.69% | -43.82% | -130.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.00% | -72.49% | -59.69% | -43.82% | -130.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.00% | -72.49% | -59.69% | -43.82% | -130.36% |
| EBIT | -26.45% | -4.10% | 8.17% | 9.44% | -25.50% |
| EBITDA | -31.40% | -7.45% | 8.37% | 10.89% | -24.80% |
| EPS Basic | 96.02% | 39.46% | 29.43% | 33.41% | 21.35% |
| Normalized Basic EPS | 99.28% | 43.41% | 32.81% | 36.09% | 21.35% |
| EPS Diluted | 95.25% | 44.91% | 35.18% | 37.58% | 13.17% |
| Normalized Diluted EPS | 95.72% | 33.74% | 23.81% | 29.27% | 26.95% |
| Average Basic Shares Outstanding | 1,149.48% | 1,060.67% | 669.08% | 324.19% | 152.70% |
| Average Diluted Shares Outstanding | 1,412.11% | 1,422.93% | 1,136.39% | 950.65% | 181.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |